Cipla inks exclusive licensing agreement with SBP Group for ADC Rolditamig Deuderuxtecan
Cipla said that it has entered into an exclusive license and supply agreement with Chia Tai Tianqing Pharmaceutical Group Co. for Rolditamig Deuderuxtecan, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
